Julien Bollard

806 total citations
16 papers, 457 citations indexed

About

Julien Bollard is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Julien Bollard has authored 16 papers receiving a total of 457 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Julien Bollard's work include Neuroendocrine Tumor Research Advances (7 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Sarcoma Diagnosis and Treatment (2 papers). Julien Bollard is often cited by papers focused on Neuroendocrine Tumor Research Advances (7 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Sarcoma Diagnosis and Treatment (2 papers). Julien Bollard collaborates with scholars based in France, United States and Canada. Julien Bollard's co-authors include Amaia Lujambio, Anu Venkatesh, Shigeki Nakagawa, Mark P. Roberto, Yujin Hoshida, C. Billie Bian, Pedro Molina-Sánchez, Verónica Miguela, Josep M. Llovet and Christie B. Nguyen and has published in prestigious journals such as Blood, Cancer Cell and Gut.

In The Last Decade

Julien Bollard

14 papers receiving 454 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Julien Bollard France 8 241 217 120 92 76 16 457
Cathy E. Nolan United States 6 384 1.6× 206 0.9× 61 0.5× 41 0.4× 117 1.5× 8 585
Arthur Groy United States 6 497 2.1× 279 1.3× 122 1.0× 25 0.3× 109 1.4× 7 696
Kelly E. Fisher United States 4 434 1.8× 288 1.3× 76 0.6× 21 0.2× 91 1.2× 6 599
Lany Ruslim United States 6 308 1.3× 155 0.7× 86 0.7× 20 0.2× 83 1.1× 6 514
Laura Kirby Australia 8 169 0.7× 245 1.1× 128 1.1× 49 0.5× 30 0.4× 11 362
Max Schreuer Belgium 11 258 1.1× 526 2.4× 113 0.9× 75 0.8× 47 0.6× 20 727
Michael Grondine United States 8 421 1.7× 265 1.2× 67 0.6× 15 0.2× 50 0.7× 14 544
Xueqian Gong United States 8 304 1.3× 294 1.4× 214 1.8× 14 0.2× 97 1.3× 16 581
Vishnu Kumarasamy United States 14 271 1.1× 360 1.7× 258 2.1× 44 0.5× 33 0.4× 22 621
Gianmarco Motta Italy 9 194 0.8× 127 0.6× 85 0.7× 19 0.2× 38 0.5× 18 395

Countries citing papers authored by Julien Bollard

Since Specialization
Citations

This map shows the geographic impact of Julien Bollard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julien Bollard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julien Bollard more than expected).

Fields of papers citing papers by Julien Bollard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julien Bollard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julien Bollard. The network helps show where Julien Bollard may publish in the future.

Co-authorship network of co-authors of Julien Bollard

This figure shows the co-authorship network connecting the top 25 collaborators of Julien Bollard. A scholar is included among the top collaborators of Julien Bollard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julien Bollard. Julien Bollard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Dubois, Valérie, Marie Balsat, Sophie Ducastelle, et al.. (2025). HLA diversity is associated with TKI response and treatment‐free remission in chronic myeloid leukemia. HemaSphere. 9(11). e70261–e70261.
2.
Vanacker, Hélène, Alexandra Meurgey, Julien Bollard, et al.. (2024). Brief Communication on MAGE-A4 and Coexpression of Cancer Testis Antigens in Metastatic Synovial Sarcomas: Considerations for Development of Immunotherapeutics. Journal of Immunotherapy. 48(1). 27–31. 3 indexed citations
3.
Chardon, Laurence, Valérie Hervieu, Léa Payen, et al.. (2024). Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms. Endocrine Related Cancer. 31(6).
4.
Feng, Xiaolan, Laurie Tonon, Haocheng Li, et al.. (2023). Comprehensive Immune Profiling Unveils a Subset of Leiomyosarcoma with “Hot” Tumor Immune Microenvironment. Cancers. 15(14). 3705–3705. 6 indexed citations
5.
Žáčková, Daniela, Franck E. Nicolini, Fausto Castagnetti, et al.. (2023). Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy. Blood. 142(Supplement 1). 6360–6360. 2 indexed citations
6.
7.
8.
Bollard, Julien, Laurence Chardon, Nicolas Gadot, et al.. (2019). Neuropilin‐2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumors. The Journal of Pathology. 249(3). 343–355. 7 indexed citations
9.
Bollard, Julien, Isabelle Goddard, Nicolas Gadot, et al.. (2017). Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells. Molecular Cancer Therapeutics. 17(1). 60–72. 8 indexed citations
10.
Bollard, Julien, Justine Lebeau, Cécile Vercherat, et al.. (2017). mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines. Oncotarget. 8(13). 20974–20987. 9 indexed citations
11.
Bollard, Julien, Verónica Miguela, Marina Ruiz de Galarreta, et al.. (2016). Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 66(7). 1286–1296. 206 indexed citations
12.
Bollard, Julien, Cécile Vercherat, Colette Roche, et al.. (2016). Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors. Investigational New Drugs. 34(5). 654–662. 19 indexed citations
13.
Karoulia, Zoi, Yang Wu, Tamer A. Ahmed, et al.. (2016). An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. Cancer Cell. 30(3). 485–498. 141 indexed citations
14.
Bollard, Julien, Cécile Vercherat, Florian Lépinasse, et al.. (2015). The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors. Oncotarget. 6(34). 36731–36745. 23 indexed citations
15.
Bollard, Julien, Yohann Couté, Gilles Poncet, et al.. (2014). Mechanisms of local invasion in enteroendocrine tumors: Identification of novel candidate cytoskeleton-associated proteins in an experimental mouse model by a proteomic approach and validation in human tumors. Molecular and Cellular Endocrinology. 399. 154–163. 6 indexed citations
16.
Bollard, Julien, Gilles Poncet, Florian Lépinasse, et al.. (2013). Antitumor Effect of Everolimus in Preclinical Models of High-Grade Gastroenteropancreatic Neuroendocrine Carcinomas. Neuroendocrinology. 97(4). 331–340. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cathy E. Nolan Breakdown of academic impact, for papers by Arthur Groy Breakdown of academic impact, for papers by Kelly E. Fisher Breakdown of academic impact, for papers by Lany Ruslim Breakdown of academic impact, for papers by Laura Kirby Breakdown of academic impact, for papers by Max Schreuer Breakdown of academic impact, for papers by Michael Grondine Breakdown of academic impact, for papers by Xueqian Gong Breakdown of academic impact, for papers by Vishnu Kumarasamy Breakdown of academic impact, for papers by Gianmarco Motta
Rankless by CCL
2026